S. Lindsey Davis, M.D.
University of Colorado Cancer Center
University of Colorado Denver
Mail Stop 8117
12801 East 17th Avenue Room L18-8105
Aurora, Colorado 80045
Phone: (303)724-8681 Fax: 303-724-3889
Sarah.Davis@ucdenver.edu
Education
Hematology and Oncology Fellowship, University of ColoradoDenver, Anschutz Medical Campus, Aurora, Colorado
Internal Medicine Residency, University of Colorado-Denver,
Anschutz Medical Campus, Aurora, Colorado
Medical Degree, University of Missouri-Columbia School of Medicine,
Columbia, Missouri
Bachelor of Science in Microbiology (Summa Cum Laude),
University of Arkansas, Fayetteville, Arkansas
Current Position
Assistant Professor
University of Colorado-Denver
Aurora, Colorado
2011-2014
2007-2010
2003-2007
1999-2003
2014-Present
Professional Experience
Chief Fellow
Division of Medical Oncology
University of Colorado-Denver, Anschutz Medical Campus
Aurora, Colorado
2013-2014
Chief Resident
Department of Internal Medicine
University of Colorado-Denver, Anschutz Medical Campus
Aurora, Colorado
2010-2011
Certification and Licensure
Diplomate, American Board of Internal Medicine
Colorado State Medical License (active)
Drug Enforcement Agency License (active)
2010
2010
2010
Professional Memberships and Activities
American Society of Clinical Oncology
2012-Present
Honors and Awards
ASCO/AACR Methods in Clinical Cancer Research Workshop Participant
2013
Committee Assignments and Administrative Services
Hematology/Oncology Fellowship Program Evaluation Committee
University of Colorado Hematology-Oncology Fellowship Selection Committee
Schwartz Center Rounds Planning Committee
Hematology/Oncology Fellowship Quality Improvement Project Leader
University of Colorado Internal Medicine Student Evaluation Committee
University of Colorado Internal Medicine Residency Selection Committee
2014-Present
2013-Present
2013-Present
2012-2014
2010-2011
2009-Present
Your Name, date
Page 2 of 2
Educational Activities
Teaching Experience
Medical Student Core Curriculum Lecturer
Hematology and Oncology Grand Rounds Lecturer
Internal Medicine Grand Rounds Lecturer
Medical Student Board Review Lecturer
Medical Student Physical Exam Course, Small Group Leader
Medical Student Internal Medicine Lecture Series, Coordinator and Lecturer
Educational Course Participation
Practical Application of Molecular and Cell Biology Techniques for the Clinical
Investigator
3/2014
3/2012, 3/2013, 1/2014
11/2010
2011
2010-2011
2010-2011
2012
Publications
1.
2.
3.
4.
5.
Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K,
Davis SL, Want T, Albadine R, Schultz L, Partin AW, Jimeno A, et al. “A
pharmacodynaimc study of rapamycin in men with intermediate- to high-risk
localized prostate cancer.” Clinical Cancer Research. 2010; 16(11):3057-66.
Davis SL and Jimeno A. “Metastatic Colorectal Cancer: Focus on
Panitumumab.” Clinical Medicine Reviews in Oncology. 2010;2:109-121.
Davis SL, Eckhardt SG, Messersmith WA, and Jimeno A. “The Development
of Regorafenib and its Current and Potential Future Role in Cancer Therapy.”
Drugs of Today. 2013; 49(2): 105-115.
Pitts TM, Davis SL, Eckhardt SG, and Bradshaw-Pierce EL. “Targeting
Nuclear Kinases in Cancer: Development of Cell Cycle Kinase Inhibitors.”
Pharmacology and Therapeutics. 2013. Advance online publication http://
dx.doi.org/10.1016/j.pharmthera.2013.12.010.
Davis SL, Eckhardt SG, Tentler JJ, and Diamond JR. “Triple-Negative Breast
Cancer: Bridging the Gap from Cancer Genomics to Predictive Biomarkers.”
Therapeutic Advances in Medical Oncology. 2014. Advance online publication.
DOI: 10.1177/1758834013519843.
2010
2010
2013
2013
2014
Manuscripts Accepted for Publication
1.
2.
3.
Kessler E, Davis SL, Brittain P, Leong S, Eckhardt SG, and Lieu CH.
“Targeted Therapies” American Cancer Society Textbook of Cancer
Micel LN, Tentler JJ, Tan AC, Selby HM, Brunkow KL, Robertson KM, Davis
SL, Pitts TM, Gangolli E,Fabrey R, O’Connell SM, Vincent P, Eckhardt SG.
“Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines
and patient-derived tumor explants.” Molecular Cancer Therapeutics.
Tocce K, Davis SL. “Hematologic Abnormalities” Contraception for the
Medically Challenging Patient
Abstracts and Presentations
Posters
Local/Regional Meetings
Pre-Postatectomy Rapamycin in Men with Advanced Localized Prostate Cancer
University of Colorado Department of Medicine Research Day
National/International Meetings
A First-in-human Phase I Study of the Novel Cancer Stem Cell (CSC) Targeting
Antibody OMP-52M51 (anti-Notch1) Administered Intravenously to Patients with
Certain Advanced Solid Tumors
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer
Therapeutics
11/2008
10/2013